Recent financing will drive Company towards second interim analysis on pivotal Phase III TIGeR-PaC clinical trial by end of 2024 LOS ALTOS, Calif., February 06, 2024--(BUSINESS WIRE)--RenovoRx, Inc. (...
Source LinkRecent financing will drive Company towards second interim analysis on pivotal Phase III TIGeR-PaC clinical trial by end of 2024 LOS ALTOS, Calif., February 06, 2024--(BUSINESS WIRE)--RenovoRx, Inc. (...
Source Link
Comments